The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC

被引：1

作者：

Ardeshir-Larijani, Fatemeh ^{[1
]}

Ramalingam, Suresh S. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2024年 / 21卷 / 11期

关键词：

D O I：

10.1038/s41571-024-00938-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.

引用

页码：767 / 768

页数：2

共 50 条

[41] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
Laurila, Niina
Koivunen, Jussi P.
MEDICAL ONCOLOGY, 2015, 32 (07)
[42] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
Remon, J.
Steuer, C. E.
Ramalingam, S. S.
Felip, E.
ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
[43] Predicting duration of response to EGFR TKI among EGFR-mutant NSCLC patients.
Sakr, Lama
Kasymjanova, Goulnar
Small, David I.
Cohen, Victor
Galvis, Luisa
Pepe, Carmela
Agulnik, Jason Scott
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[44] Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC
Pham-Danis, Catherine
Gehrke, Sarah
Danis, Etienne
Rozhok, Andrii, I
Daniels, Michael W.
Gao, Dexiang
Collins, Christina
Di Paola, Jose T.
D'Alessandro, Angelo
DeGregori, James
MOLECULAR CANCER RESEARCH, 2019, 17 (06) : 1351 - 1364
[45] Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)
Liang, W.
Xu, E.
Zhao, J.
Wang, M.
Zhang, Z.
Liang, Y.
Cheng, C.
Wang, G.
Zhong, C.
Liang, Z.
Chen, X.
Zheng, B.
Huang, Y.
Hu, J.
Xu, L.
Xie, M.
Liang, N.
Xu, S.
Liu, J.
Wei, L.
Peng, Z.
Zhang, G.
Zhang, S.
Xu, S.
He, J.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S285 - S286
[46] Tamoxifen Might Enhance the Effect of EGFR-TKIs on EGFR-Mutant NSCLC Cells
He, Y.
Zhang, Q.
Zheng, M.
Chen, Z.
Wei, X.
Yang, X.
Gao, X.
Wu, Y.
Liu, S.
Zhou, Q.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S242 - S242
[47] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
Niina Laurila
Jussi P. Koivunen
Medical Oncology, 2015, 32
[48] Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma
Shulman, Katerina
Kazarin, Olga
Tannous, Elias
Sofer, Orit
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (06): : 385 - 386
[49] Musashi-2 regulates EGFR expression in NSCLC, cell proliferation and survival, response to EGFR inhibitors in EGFR-mutant NSCLC
Kudinov, Alexander
Makhov, Petr
Faezov, Bulat
Bychkov, Igor
Deneka, Alexander
Nicolas, Emmanuelle
Caid, Kathy Q. Q.
Brebione, Rohan
Avrilf, Eleanor
Nikonova, Anna S.
Serebriiskii, Ilya G.
Borghaei, Hossein
Golemis, Erica A.
Boumber, Yanis
CANCER RESEARCH, 2019, 79 (13)
[50] Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
Wang, Kaiwen
Du, Robyn
Myall, Nathaniel J.
Lewis, Whitney E.
Uy, Natalie
Hong, Lingzhi
Skoulidis, Ferdinandos
Byers, Lauren A.
Tsao, Anne
Cascone, Tina
Pozadzides, Jenny
Tu, Janet
Negrao, Marcelo, V
Gibbons, Don L.
Park, Keunchil
Rinsurongkawong, Waree
Lee, J. Jack
Gandara, David
Behl, Deepti
Shu, Catherine A.
Riess, Jonathan W.
Baik, Christina
Wakelee, Heather A.
Vaporciyan, Ara A.
Heymach, John, V
Zhang, Jianjun
Le, Xiuning
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 500 - 506

← 1 2 3 4 5 →